Medtronic’s Spinal Cord Stimulator Resolves Pain In Vectors Postmarket Study
Executive Summary
Most patients treated for chronic leg and back pain with Medtronic’s Intellis spinal cord stimulator with the Evolve workflow in the Vectors study showed improved symptoms and function.
You may also be interested in...
Saluda’s Evoke SCS Set To Join Competitive US Spine-Stim Market In Late 2022
The Australian company secured $125m in financing to support commercialization of the Evoke SCS system for chronic pain beginning in late 2022. The US FDA approved Evoke SCS for chronic intractable pain of the trunk and/or limbs, the third major FDA approval of an SCS technology this year so far.
Brain Therapies Leads Medtronic’s Growth In First Quarter Of Fiscal 2020
The medtech giant reported revenue of $7.5bn in the quarter that ended on 26 July, up 3.5% year-over-year basis, led by 12.5% growth in revenues from emerging markets. Medtronic’s fastest-growing business is its brain therapies unit, which reported 11.4% growth in the quarter.
Medtronic And Boston Scientific Finance Saluda's Neuromodulation System
Saluda Medical has secured funds from Medtronic and Boston Scientific to support the development of its spinal cord stimulation system for pain management.